Drug Profile
Birch allergy vaccine - NIOX
Latest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Circassia
- Developer NIOX
- Class Allergens; Peptide vaccines; Peptides; Skin disorder therapies; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 05 Sep 2018 Phase-II development is ongoing for Birch allergy vaccine (Corporate presentation,
- 01 Jul 2016 Circassia completes a phase-II clinical trial in Seasonal allergic rhinitis in Canada (unspecified route)
- 01 Jul 2015 Phase-II clinical trials in Seasonal allergic rhinitis in Canada (unspecified route)